for more, novavax ceo stan erck. huge development, but there is an "if," you need approval from the european medicines agency. what is the status of that? stan: we have three major announcements. one was the signing of the agreement with the eu, which says there is continued significant demand for our product. the second was we have data that just came out that shows our vaccine works really well and this can be very effective against the variants, and the -- those data were prepared today. the third, and these all fit together very well, is that we have now filed our first regulatory filing for approval of the vaccine for authorization. we filed it first in india and indonesia and the philippines. india is the country we are working with our partner. they know that process and have been working with the d cgi very closely. that is why we got early filing there. indonesia and philippines are desperate for vaccines and are following, we filed with them too. this is just the first filing. we will be filing with the eur

. >>> shares of novavax taking a beating after the emergency use authorization for its candidate. >>> and key pressure on powell over the easing of the monetary policy. >>> and jamie dimon's skepticism of cryptocurrency. jpmorgan chase giving clients its access to that sector. it is friday, august 6th here are on "worldwide exchange." >>> good morning i'm dominic chu in for brian sullivan here is how your money and the global markets are setting up. stock futures are slightly, i mean ever so slightly to the down side for the nasdaq implied lower by 14 points dow implied higher by 3 points the s&p is flat right now. all of this a holding pattern ahead of the jobs report all three major indices finishing in the green thursday with the s&p 500 and nasdaq closing at record highs. s&p 500 with the 43rd record close of the year. the nasdaq closing its 27th. the dow is half a percent away from its own record high turning to the bond market 10-year yield. holding steady at 1.24%. 2-year treasury yield 0.21%. investors are dpegearing up fore jobs report at 8:30 a.m. eastern time estimates from

shery: stanley erck, novavax ceo.htening curves as the delta variant continues to spread. let's bring in our senior -- medical reporter michelle cortez. what are some of the more significant moves we are seeing? michelle: we're seeing lockdowns across asia happening right now. in australia, two thirds of the country is in lockdown. they've been asked to stay home. they are curbing all sorts of activities outdoors. we are seeing the same situation in china, experiencing its most broad outbreak since the virus began percolating in you -- wuhan a year and a half ago. there are fewer cases happening in china but they paid -- take the virus very seriously so they are having things like restricting and putting people into quarantine even when they come from other places within china when they go to beijing. australia to china and other places, lockdowns are happening everywhere. shery: of course, we are seeing sydney's lockdown continuing in melbourne going into its sixth lockdown. the vaccination rate is an issue. michelle

novavax on the upside one and half percent. in the u.s.accine, pause funding for the novavax vaccine. stock is up. susan: that's interesting to me. we had the u.s. government ordering novavax to stop making the vaccine in the u.s. because of manufacturing standards with concerns. they are not getting any more government funding as well. novavax still has not gotten emergency authorization and you have pfizer and moderna already on track to possibly get final approval this fall but i would say novavax, there was a bullish tailwind because they had the eu offering to buy 200 million doses. stuart: contradictory news between the contradiction of the news and the stock price performance. can't explain that. how about moderna since we are talking vaccines? despite their vaccine having 92% efficacy rate formants after the second shot they say fully vaccinated people will still need a booster shot before the end of the year. if you need a booster shot, you need moderna so what does the stock by 2% 422, extraordinary run. draftkings surging as the

they, like ours, where heroes of the pandemic and now some of them are novavax. show them that they are the ones at fault. at the arena, the show will go on, but with new checks for the opera lovers. it italy is beginning another act and its story, but the unity built last year is fading. stay with us on bbc news, still to come: more on the skateboarding, a breakout success and the tokyo games. the question was whether we wanted to save our people — and japanese as well — and win the war or whether we wanted to take a chance on being able to win the war by killing all our young men. the invasion began at two o'clock this morning. mr bush, like most other people, was clearly- caught by surprise. we call for the immediate and unconditional withdrawal of all iraqi forces. 100 years old and still full of vigour, vitality and enjoyment of life — no other king or queen in british history has lived so long, and the queen mother is said to be quietly very pleased indeed that she has achieved this landmark anniversary. this is a pivotal moment for the church as an interna

novavax says it asked next to apply for emergency use of covid in the -- for the covid vaccine in thearter. in a trial in the u.s. and mexico, the vaccine was 90% effective with relatively few side effects. it is approved for emergency clearance in india and the philippines read global news, 24 hours a day. powered by more than 2700 journalists and analysts. this is bloomberg. dani: thanks so much. coming up his dogs day -- jobs day. we will discuss america's labor market, next. this is bloomberg. ♪ dani: welcome back to bloomberg daybreak: europe. we had some breaking news. alibaba set to face higher taxes from chinese authorities. the hang seng stocks hong kong reversing their gains. looking at a hang seng that is lower by about 0.1% rate alibaba slightly weaker as well. they were up ever so slightly, now they are down zero 3%. china and the focus as well as what is happening the u.s.. 60,000 is more so. this jobs day getting more importance pinned onto it after a plethora of fed speakers laying out a sketch for where things go. how much that depends on the data we see over the next

officials will begin assessing five other candidates this month, including novavax and sinopharm vaccine. russia's vaccine is still undergoing assessment by the who . it has already approved vaccines made by pfizer, moderna, astrazeneca, and johnson & johnson. moderna will double enrollment in its trial of children under 12, following a request from u.s. regulators to collect additional safety data. the study will register thousands of participants, six months to 12 years old. modernity said it would seek to enroll 7000. china's central bank is facing calls to cut interest rates, as fresh virus outbreaks threaten to derail recovery. government-affiliated, argue that success in curbing growth means that pboc can ease. this contrasts with global investment banks, seeing the pboc keeping great study for now. global news 24 hours a day on air and on quicktake powered by more than 2700 journalists and analysts in more than 120 countries. i am vonnie quinn. this is bloomberg. >> still ahead, more insight on inflation risks, the biden spending plan, with our guest later this hour. next, our int

shot or the johnson & johnson shot, would it be safe and effective to get a pfizer or moderna or novavax whenever that comes online as a booster shot. stay tuned, there will be more data there. there is preliminary data that suggests it is safe and likely effective but there should be a more definitive answer. host: we have a viewer on twitter asking, what happened to the inexpensive rapid tests that were promised. i can't be vaccinated and rapid test should be one of the tools we are using. andrew: that's a great question. the response to the pandemic should not just be vaccines, it should be billing diagnostic vaccines and therapeutics. it's been surprising to see the lack of uptake among that and at home quick, easy, and cheap come of the diagnostic tests to tell if you have covid can help identify and isolate cases on the mild side among the vaccinated who might not be as inclined to go to a mass testing site. if they are vaccinated it's not likely to be a severe illness at the end of the day. if there was a cheap at-home test that would be helpful and i'm not totally clear about why

we are looking at novavax in india, indonesia and the philippines, struggling with a slow vaccine rolloutnd a rise in cases. >> in india we are working with our partner. they know the process has been working with the fda of india closely and that is why we have an early filing. indonesia and the philippines are desperate for vaccines. they are following -- they are filing and we filed with them. >> let's check in on markets. we have been talking about malaysia, a televised briefing out of the health ministry, talking about a rise in covid cases, now due to the dominance of the delta variant. in indonesia, a big trading debut, the biggest ipo on record in the country, 25% up. we will bring up this next chart and you will see this, priced to sales. we talked about valuations. this makes sense. not apples to apples but we looked at price to sales. everything from amazon to ebay, jd.com, different markets, different multiples but we are in the low single digits when you look at market caps and revenue. i'm doing math in my head. if it is valued at $6 billion and my understanding is there las

novavax striking a deal with the eu to secure up to 200 million doses of the company's covid vaccine. >> and next, camping world beating earnings and rech knew estimates and increasing its buy back program baird upgrading higher to 6% >> a lot of people want rvs to go on trips. and finally nikola bouncing back the growing legal issues surrounding its founder still down 24% for the week but higher by 5% today. >> that story gets more complicated. ahead, we'll speak to one analyst who says the surging delta variant won't stunt u.s. growth >> the next stop in our powerhouse road trip we will discuss whether the red-hot housing market shows any signs of slowing down. we'll take you to a mystery city in the mdlide west see if you can guess i ♪ ♪ ♪ ♪ more diverse thinking leads to more unexpected, more thoughtful solutions. ♪ and there you have it - wireless on the fastest, most reliable network. wow! more thoughtful solutions. big deal! we get unlimited for just $30 bucks. i get that too and mine has 5g included. impressive. impressive is saving four hundred bucks a year. four bucks? that'

novavax down 10%. they had a very good trial with regards to their covid vaccine.em is they still haven't submitted it for approval here in the u.s. the problem is they manufacturing guidelines quite meet fda standards. they are pushing back. there is submission for authorization till the fourth quarter. that is at least the second delay we have seen out of nowhere. a few other names to keep an eye on this morning, didi shares getting a bit of a bid. they may find a way to comply with the latest regulatory issues over there in china. fireeye stocks down as well, as is mobile gaming company zynga. tom: ellen zentner joins us now, of morgan stanley. how has your x axis changed? our great debate at "surveillance" is the idea of a boom economy back somewhere to normal. tell us your 2021, 2022, 2023 in the labor market. ellen: it will be a slow way back for support. we saw a drop that we have never seen in history. i think 1% was the historical biggest number, and then it can take years to climb back to pre-downturn levels. so it is just going to be a slow slog. we are

and novavax up 6%. watch those vaccine makers and then speaking of, it's pfizer related news but not vaccine for covid related. pfizer shares were short again but tritium therapeutics up 189% pfizer is going to buy the remaining shares of tritium it doesn't know the reason i'm going to show you here alx oncology holdings trillium does cancer treatments. that's what pfizer wants to get. alx is also a cancer therapeutics make r e. that stock is up 15% in sympathy some sellers or investors and speculators may think what other companies are out there in play. al alx is one of them that's why it's up in that session. we'll send things back to you. >> there's been a slow spate of activity for small cap biotech stock. so, big news today on many fronts dom, thanks. >> you got it. >>> stocks in general are hitting new highs ahead of the jackson hole meeting this week is the fed tapering over weak fundamentals or is earnings strong enough to justify chief investment officer at huptington private bank joins me joh

and novavax. so we hope that, over the next six-to-nine months, the supply issue gets solved.ow, whenever you have an elderly person, you know, in south america or in africa who dies of covid, you know, it's an injustice because other people who are far -- at far less risk, got the vaccine before they did. >> along those same lines, what do you think about the right answer is on booster shots? israel's already started administering third doses to people over 60. the world health organization, today, asked for all booster doses to be halted until at least the end of september so more doses can be distributed to developing nations. obviously, officials in the u.s. haven't made a decision on boosters, yet. what is the right thing to do? >> in the next few months, the boosters should be reserved for people who, clearly, have antibody waning. that is, people who have weak-immune systems, like people living with hiv. and it's a pretty modest percentage of the population. the beauty of that is, then, we'll be able to get a lot of supply out to the world. and really, understand the be

. >>> all right, novavax getting slammed until it is delaying approval until the fourth quarter.quarter. down 20%. this as the urgency for vaccines has been growing with the delta variant's rapid spread. we'll talk about that. hospitalization rates are climbing across many parts of the country. the ceo of -- will be here on the fight being waged against the pandemic's, i guess, fourth wave at this point. about half an hour to go in the trading day, the dow's up 139. the s&p 500 also looks like it may close at yet another record high, but the nasdaq's pulling back down about one-half of 1%. we'll be right back. ♪ reward, i see one element securing portfolios, time after time. gold. your strategic advantage. all the time in the world. it's just a saying. but today, for women living with hr+, her2- metastatic breast cancer. more time is possible with verzenio. proven to help you live significantly longer when taken with fulvestrant. verzenio + fulvestrant is for hr+, her2- metastatic breast cancer that has progressed after hormone therapy. diarrhea is common, may be severe, or cause

novavax says it expects to apply for emergency use authorization in the fourth quarter, signaling anothern a bid to gain approval. in a trial in the u.s. and mexico, the vaccine was 90% effective with relatively few side effects. it has been filed for emergency see clarence and indonesia and the philippines. nintendo shares -- the company maintained its forecast with chip shortages weighing on production. that is the bloomberg business flash. anna: corporate news very much in the news. the shipping giant merck, saying the outlook for the third quarter is strong. the global shipping boom expected to keep growing. it did upgrade earlier this week. the company announced it is buying two companies. join us on bloomberg is the mer sk ceo. telus, what will these two purchases enable you to do that you cannot do already? >> it is accord limit of our strategy to grow. being able to sell more logistics services to our ocean customers. we grew at 38% in the same quarter year after year. we are increasing our capability in the fastest-growing segment. namely, e-commerce. we will be able to offer cus

. >> though there is misother that may follow like novavax, but i think you'll start to see boosting become recommended starting tomorrow, and i think as we wrote in a note this week battery recharge time. maybe we'll get to -- i think it's a battery recharge time and a proportion of people will feel comfortable getting a boost over the next year. >> i do know some people who have gotten no reaction, and some people have gotten adverse reactions that hung around so it's going to be a key question to see whether people are willing to line up for that booster shot again that being said, moderna is up triple digits just since the start of this year this couldn't didn't have it on the market before. what would change your rating? what do you as the next leg or key catalyst for the start the first is what is driving the stock? we wrote a note about it last week we called it the tesla of biotech. i said battery recharge against this weekend that's because tech investors, generalist investors, global investors view it as a disruptive innovative platform i think that's why people it ca proba

to like roku, but that's the near-term -- >> thank you so much >>> meg tirrell has the details on novavax this earning report probably more to do with the timelines. it's pushing back its planned submission of the emergency use authorization to the fda now to the fourth quarter it believely said it planned to do that in the third quarter, so you're seeing it down more than 12% on this news it is saying it's planning to file in other countries earlier than the u.s here it is use might be questionable for anything other than po stenchally booster, given that we're already losing demand for covid vaccines at this point positive data on boosters, but we'll have to see what role this vaccine ends up playing. >> didn't they recently sign something with europe that got investors all excited? >> they did. we'll have to wait and see how their vaccine will get used. >> meg, thank you. down almost 14 pu%. >>> up next, the ceo on bed bath bon 'lbe right back. at pnc bank, we believe in the power of the watch out. that's why we created low cash mode, the financial watch out that gives you the options

haidi: especially with that novavax announcement., profit in the vision fund sinking 90% in the first quarter. the ceo also said that softbank has no plans to buy back shares per now -- shares for now. our next guest, atul goyal, bloomberg's top ranked analyst for softbank. you were surprised, a lot of people were disappointed, and a lot of people were saying this kind of removes a floor for how much these shares could fall now. >> based on the discussions we have had, we believed there would be a very high chance of buyback. what they have said is for now, they are not doing it. but, in response to our questions on the call later on, it was stated that the were actively discussing the timing and sizing of these buybacks. at the same time, quite a few of our investors did not believe they were ready for buybacks. they were questioning about the funding because softbank has been investing funds into vision fund 2 investments. so, we did expect a buyback to be announced. and may, buying back at about ¥10,000 per share. other stock is b

global health officials will begin assessing five other candidates this month including novavax shot sinopharm vaccine being made in wuhan, china. the sputnik vaccine is undergoing assessment by the world health organization. the who has already approved vaccines made by pfizer, moderna, astrazeneca, and johnson & johnson. moderna plans -- in a trial of its covid-19 vaccine in children aged 12. this follows a request from u.s. regulators to collect an safety data. drugmakers study will register and mated 13,275 participants aged six months to 12 years old according to a government website. in a post from late july, mentor said it would seek to enroll about 7000. they have updated messaging to recommend pregnant women get vaccinated against covid-19. new research shows women who receive messenger rna covid vaccine before 20 weeks of pregnancy had no increased risk of miscarriage or other safety concerns. the fda will amend the emergency use of pfizer and moderna vaccine to allow those with compromised immune systems to get a third dose. the u.s. has won a bid to expand the scope of it

. >> it is not free vaccines, wills forget about astrazeneca, and now novavax have a vaccine. the soviet and the chinese and vaccines are produced. it is amazing to see this many agents. i thank you for your simoni. -- i thank you for your testimony. rep. eshoo: the gentleman yields back. a gentlewoman from california, you have five minutes for your questions. >> thank you. how want to thank the witnesses -- i want to thank the witnesses for being here today. health-care workers have been true heroes from this pandemic. the large number of nursing home staff not been vaccinated against covid-19. despite the devastating impact the virus has had, living in nursing homes and long-term care facilities. a lot of these health care workers are seeing consequences wendy vaccine was not available -- when the vaccine was not available. nursing home residents received at least one dose of the vaccine, only half of -- or vaccinated. -- were vaccinated. >> we have done work in nursing homes. at house -- it has to do with the education of the nursing aides. it resides in the nursing a popul

is in the first place, followed by china and russian athletes >>> and keep an eye on novavax they reachion doses of the vaccine candidate. dow's down 175 the personal loan from sofi helped me consolidate my credit card debt into one simple monthly payment. debt free! thanks to sofi. ♪♪ i think you're going to like it here. umm, why is everyone... throwing things at me? look, as cfo it's my job to be ready for whatever's next. that's why i have my finance team, randomly hurl things at me. it's also why we use workday. it gives us insights, so we quickly pivot our strategy, people, planning, you name it. sorry, sir. i will aim straight at your next step. see that you do. would you like some coffee? workday. the finance, hr, and planning system for a changing world. ♪ >>> could a key sectore b breaking down a. br. as your broker, i've solved it. that's great, carl. but we need something better. that's easily adjustable has no penalties or advisory fee. and we can monitor to see that we're on track. like schwab intelligent income. schwab! introducing schwab intelligent income. a simple, mod

recommend covid-19 boosters for all americans, after their second dose you can see names like moderna and novavaxme depot down 5% beth out with results. hey, court >> hi g to see you so, the two dow components beating on earnings and revenue. walmart coming in stronger than expected and home depot disappointed walmart with a 6% growth in transactions this quarter t was stores that led the way with store traffic continuing to grow at walmart. the e net commerce grew 6% that's a much smaller increase than they're used to seeing. last year they grew 97%. and the retailer expecting global commerce to hit 75 billion this year. that's x-marketplace goods walmart put up the third biggest quarterly revenue ever and raised its earnings revenue and comp sales guidance. brett bigs says the third quarter is off to a good start with a really good start to back to school. and shares up a quarter of a percent. home depot growing 4.5% total, 3.4% in the u.s. and that's growth on top of 25% last year in the same quarter. still both of those were below the street's expectations. home improvement has been a big ben

novavax announcing it will delay submission of vaccine until the fourth quarter and saw revenue fall street's estimates. those are down 19.5% as well cautious guidance tied to covid-related uncertainty. those shares are down about 2% right now. and david, i'll kick it over to you. >> i'll take it. >>> the u.s. economy adding jobs steve. >> a big, strong jobs number has some forecasters thinking that momentum is building in the jobs market could be more big numbers yet to come david gave you the top line, 943. 10 120,000 added in revisions maybe it's currently still a pandemic and one-tick better as wages continue to surge. 61.7 up a tick but still depressed from where it was in february 2020 the idea that many workers remain on the sidelines, that's behind the optimism, depending on the impact of the delta variant. assuming the variant doesn't force renewed containment measures, we maintain the positive outlook in the past and see them recouping over 7 million jobs this year local education. that was a bit of a statistical quirk because there weren't a lot fired. so, there weren't se

biontech up and novavax up 2.25% as well.covid may advance the shares follow-up to come. and victor yapp secret not public a stand-alone company that long. a week or so up about 20% in yesterday's session driven in large part by an analyst coverage initiation by folks over at jpmorgan. more analyst calls come the ow with equivalent of buy ratings helping drive the share this morning. victoria's secret, women's lingerie, casual stuff, looking good from a stand-alone company. up 3.25% in the pre-market over to you. >> and moderna, number one ticker on cnbc.com surprising, but not given the stock's amazing run this year. >> yesterday's session maybe not a surprise so much activity price action tends to draw attention in search traffic in those, but when moderna shares were up like yesterday, tends to draw a lot more people to see, what's going on? why is it doing this we know moderna has been -- by the way, mentioned it casually yesterday. at current levels we have, melissa, talking north of $190 billion valuation for moderna ma

stuart: up 15%, novavax. susan: vaccine maker. stuart: that will help. thank you, susan. very good on robinhood. susan: on the spot trivia. stuart: yes it was. it is pretty good. hold that for the trivia question at the end of the show. no we won't. critical race theory a capitalists, what is u.s. wokeness really about? victor david hanson is here and answers the question he posed in the headline. he is on the show shortly. new york city set to require vaccine passports to eat inside of a restaurant. the owner of bob any vann's steakhouse, says it will close more restaurant close us. he is on the show. >>> the best of america, inspiring us all with the embrace of the united states all the way from tokyo. we have her amazing story. it is a good one right after this. ♪ it's been set in motion. ♪ ♪ ♪ power can't be tempered, ♪ ♪ silenced or caged. ♪ bad things. ♪ ♪ ♪ it can only be set free. ♪ ♪ ♪ i want to make you yell. ♪ i'm searching for info on options trading, and look, it feels like i'm just wasting time. that's why td ameritr

. >> stuart: novavax. >> it has a vaccine that hasn't gotten the emergency use authorization from theg their trials. getting close to that step. what they are finding is that just two weeks, according to the cdc, after you get the second shot, you are fully vaccinated, so as we enter this time, where we're trying to get more people to be vaccinated, maybe another entrance into the market here, and that is, you know, high immunity or antibody action, if you will, in just two weeks' time after the second shot. >> stuart: it is an addition to the vaccine arsenal. >> exactly. >> stuart: stock is up 4%. i got it, thanks. let's show you drone video, looters breaking into an atm. this is an aftermath of hurricane ida. anti-looting patrols are being deployed. we got a report for you. for a long time, the u.s. and britain have had a special relationship, but will the brits trust president biden after the botched withdrawal from afghanistan? i will ask no less than nigel farage. the u.s. must now vet thousands of afghan refugees. ashley webster is in germany finding out how the vetting process

biontech, moderna, novavax at least doubling in value. profit taking still in play for these vaccine make rs, still ones to watch given that news coming out. chinese internet stocks under pressure again no surprise here new market regulator has come out and said they want to regulate the fair use of the internet and that's maybe being viewed as the next incremental step towards the bigger crackdown on its internet companies, alibaba, jd.com, baidu, off 2% to 4%. chinese internet stocks, retail in general, andrew back over to you guys. >> dom, thank you for that when we return, we'll talk about tesla's autopilot. it's facing a u.s. inquiry through a series of crashes. we'll bring you a breakdown of what this could mean for the company with investors, former ford ceo mark fields then later morgan stanley's chief u.s. equity strategist mike wilson will join us >>> plus these other great guests will be joining us. jeff blau, endeavor ceo ariemanual and kyle bass talking about afghanistan and the investor impacts quk"etns with all of it after

shot or the johnson & johnson shot, would it be safe and effective to get a pfizer or moderna or novavaxr that comes online as a booster shot. stay tuned, there will be more data there. there is preliminary data that suggests it is safe and likely effective but there should be a more definitive answer. host: we have a viewer on twitter asking, what happened to the inexpensive rapid tests that were promised. i can't be vaccinated and rapid test should be one of the tools we are using. andrew: that's a great question. the response to the pandemic should not just be vaccines, it should be billing diagnostic vaccines and therapeutics. it's been surprising to see the lack of uptake among that and at home quick, easy, and cheap come of the diagnostic tests to tell if you have covid can help identify and isolate cases on the mild side among the vaccinated who might not be as inclined to go to a mass testing site. if they are vaccinated it's not likely to be a severe illness at the end of the day. if there was a cheap at-home test that would be helpful and i'm not totally clear about why that ha